{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:29:13Z","timestamp":1788449353711,"version":"build-2803163510"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low molecular weight heparin (LMWH) is extensively utilized as an anticoagulant for the prevention and management of various thrombotic conditions. However, despite the widespread use of LMWH in clinical indications, its adverse events (AEs) have not received substantial attention, and there is a lack of systematic and comprehensive AE studies. This study aims to evaluate AE signals associated with LMWH in the overall population and in pregnancy women from the FDA Adverse Event Reporting System database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the Standardized MedDRA Query to identify pregnancy-related AE reports. Disproportionality analyses were employed to identify LMWH-related AE by calculating the reporting odds ratios (ROR), proportional reporting ratios (PRR), bayesian confidence propagation neural network (BCPNN), and the empirical Bayesian geometric mean (EBGM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For the overall population, the significantly reported adverse signals in SOCs were pregnancy, puerperium, and perinatal conditions, vascular disorders, blood and lymphatic system disorders, and product issues. The five strongest AEs signal of LMWH-related were anti factor X antibody positive (n = 6, ROR 506.70, PRR 506.65, IC 8.31, EBGM 317.03), heparin-induced thrombocytopenia test positive (n = 19, ROR 263.10, PRR 263.02, IC 7.65, EBGM 200.79), anti factor X activity increased (n = 10, ROR 255.93, PRR 255.89, IC 7.62, EBGM 196.61), heparin-induced thrombocytopenia test (n = 14, ROR 231.85, PRR 231.80, IC 7.51, EBGM 182.09), and spontaneous heparin-induced thrombocytopenia syndrome (n = 3, ROR 230.31, PRR 230.30, IC 7.50, EBGM 181.16). For pregnancy women, the five strongest AEs signals of LMWH-related included sternal fracture (n = 3, ROR 243.44, PRR 243.35, IC 6.61, EBGM 97.94), syringe issue (n = 12, ROR 97.49, PRR 97.34, IC 5.94, EBGM 61.21), bleeding time prolonged (n = 3, ROR 97.38, PRR 97.34, IC 5.94, EBGM 61.21), spinal compression fracture (n = 10, ROR 90.24, PRR 90.13, IC 5.87, EBGM 58.30), and injection site haematoma (n = 19, ROR 79.23, PRR 79.04, IC 5.74, EBGM 53.47). Additionally, unexpected AEs associated with LMWH in pregnancy women were observed, including premature baby death, placental necrosis, abortion, antiphospholipid syndrome, systolic dysfunction, compartment syndrome, body height decreased, rubella antibody positive, and ultrasound doppler abnormal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified unexpected AE signals of LMWH-relate in pregnancy women. Our study could provide valuable evidence for the clinical practice of LMWH, especially for identifying AEs and ensuring safe usage in pregnancy women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1442002","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:26:53Z","timestamp":1723422413000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database"],"prefix":"10.3389","volume":"15","author":[{"given":"Huanying","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e59933","DOI":"10.7759\/cureus.59933","article-title":"Risk assessment of ritical obstetric bleeding with low-molecular-weight heparin","volume":"16","author":"Akaishi","year":"2024","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-3-642-23056-1_10","article-title":"Adverse effects of heparin","author":"Alban","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/ATVBAHA.120.315445","article-title":"Heparin-induced thrombocytopenia: a focus on thrombosis","volume":"41","author":"Arepally","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6985020","DOI":"10.1155\/2020\/6985020","article-title":"A \"catastrophic\" heparin-induced thrombocytopenia","volume":"2020","author":"Barcellona","year":"2020","journal-title":"Case Rep. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","article-title":"A data mining approach for signal detection and analysis","volume":"25","author":"Bate","year":"2002","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"Bates","year":"2018","journal-title":"Blood Adv."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e884","DOI":"10.1016\/S2352-3026(20)30327-6","article-title":"Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study","volume":"7","author":"Beyer-Westendorf","year":"2020","journal-title":"Lancet Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S0140-6736(22)02128-6","article-title":"Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (highlow study): an open-label, multicentre, randomised, controlled trial","volume":"400","author":"Bistervels","year":"2022","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.thromres.2008.08.005","article-title":"Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency","volume":"123","author":"Clark","year":"2008","journal-title":"Thromb. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S1126","DOI":"10.1016\/j.ajog.2020.11.006","article-title":"Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis","volume":"226","author":"Cruz-Lemini","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/S2352-3026(18)30046-2","article-title":"Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study","volume":"5","author":"Dhakal","year":"2018","journal-title":"Lancet Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17512433.2024.2306223","article-title":"Metformin adverse event profile: a pharmacovigilance study based on the fda adverse event reporting system (faers) from 2004 to 2022","volume":"17","author":"Du","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/bjh.13209","article-title":"Lmwh to prevent placenta-mediated pregnancy complications: an update","volume":"168","author":"Duffett","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1161\/CIRCULATIONAHA.109.872630","article-title":"Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials","volume":"120","author":"Eikelboom","year":"2009","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (prrs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.thromres.2016.05.016","article-title":"Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density","volume":"143","author":"Galambosi","year":"2016","journal-title":"Thromb. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40800-015-0018-0","article-title":"Enoxaparin-induced liver injury: case report and review of the literature and fda adverse event reporting system (faers)","volume":"2","author":"Hahn","year":"2015","journal-title":"Drug Saf. Case Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"CD012852","DOI":"10.1002\/14651858.CD012852.pub2","article-title":"Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss","volume":"5","author":"Hamulyak","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00198-019-04842-w","article-title":"Pregnancy-associated osteoporosis: a UK case series and literature review","volume":"30","author":"Hardcastle","year":"2019","journal-title":"Osteoporos. Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","article-title":"Pharmacology of heparin and related drugs: an update","volume":"75","author":"Hogwood","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11239-009-0428-x","article-title":"The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour","volume":"30","author":"Isma","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tjog.2020.11.001","article-title":"The role of low molecular weight heparin on recurrent pregnancy loss: a systematic review and meta-analysis","volume":"60","author":"Jiang","year":"2021","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of brexpiprazole: real-world adverse event analysis from the faers database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1055\/s-0038-1648001","article-title":"Four heparin preparations: anti-xa potentiating effect of heparin after subcutaneous injection","volume":"35","author":"Johnson","year":"1976","journal-title":"Thromb. Haemost."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7649","DOI":"10.26355\/eurrev_201909_18888","article-title":"Low molecular weight heparin as cause of liver injury: case report and literature review","volume":"23","author":"Leo","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00774-021-01268-5","article-title":"Impaired bone healing by enoxaparin via inhibiting the differentiation of bone marrow mesenchymal stem cells towards osteoblasts","volume":"40","author":"Li","year":"2022","journal-title":"J. Bone Min. Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann. Intern Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"10730","DOI":"10.3390\/ijms221910730","article-title":"Molecular mechanism of the anti-inflammatory action of heparin","volume":"22","author":"Litov","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1247253","DOI":"10.3389\/fphar.2023.1247253","article-title":"Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the faers database","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/19336918.2020.1767489","article-title":"The anti-cancer properties of heparin and its derivatives: a review and prospect","volume":"14","author":"Ma","year":"2020","journal-title":"Cell Adh Migr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1160\/TH16-02-0169","article-title":"Lmwh in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis","volume":"116","author":"Mastrolia","year":"2016","journal-title":"Thromb. Haemost."},{"key":"B34","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.3390\/ijms24098217","article-title":"Novel knowledge about molecular mechanisms of heparin-induced thrombocytopenia type ii and treatment targets","volume":"24","author":"Mongirdiene","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0140-6736(23)00693-1","article-title":"Heparin for women with recurrent miscarriage and inherited thrombophilia (Alife2): an international open-label, randomised controlled trial","volume":"402","author":"Quenby","year":"2023","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1000292","DOI":"10.1371\/journal.pmed.1000292","article-title":"The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies","volume":"7","author":"Rodger","year":"2010","journal-title":"PLoS Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/S0140-6736(16)31139-4","article-title":"Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials","volume":"388","author":"Rodger","year":"2016","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1111\/jth.15848","article-title":"Variable serotonin release assay pattern and specificity of pf4-specific antibodies in hit, and clinical relevance","volume":"20","author":"Rollin","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"B40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/JBM.S232648","article-title":"Current perspectives on diagnostic assays and anti-pf4 antibodies for the diagnosis of heparin-induced thrombocytopenia","volume":"11","author":"Sahu","year":"2020","journal-title":"J. Blood Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40801-021-00287-y","article-title":"Pregnancy loss signal from prostaglandin eye drop use in pregnancy: a disproportionality analysis using Japanese and us spontaneous reporting databases","volume":"9","author":"Sakai","year":"","journal-title":"Drugs Real World Outcomes"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1063625","DOI":"10.3389\/fphar.2022.1063625","article-title":"Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: a disproportionality analysis using the Food and drug administration adverse event reporting system","volume":"13","author":"Sakai","year":"","journal-title":"Front. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s40264-017-0560-z","article-title":"Signal of miscarriage with aripiprazole: a disproportionality analysis of the Japanese adverse drug event report database","volume":"40","author":"Sakai","year":"2017","journal-title":"Drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome","volume":"34","author":"Sammaritano","year":"2020","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1016\/s0272-6386(03)00211-7","article-title":"Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin","volume":"41","author":"Sarris","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/cea.13159","article-title":"Low incidence of heparin-induced skin lesions in orthopedic surgery patients with low-molecular-weight heparins","volume":"48","author":"Schindewolf","year":"2018","journal-title":"Clin. Exp. Allergy"},{"key":"B48","doi-asserted-by":"publisher","first-page":"601","DOI":"10.7326\/M14-2062","article-title":"Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme","volume":"162","author":"Schleussner","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"257S","DOI":"10.1378\/chest.08-0674","article-title":"Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Schulman","year":"2008","journal-title":"Chest"},{"key":"B50","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.1038\/s41598-019-43715-4","article-title":"Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase\u00ae","volume":"9","author":"Sessa","year":"2019","journal-title":"Sci. Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.3390\/ijms20215275","article-title":"Anticoagulants and osteoporosis","volume":"20","author":"Signorelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e922498","DOI":"10.12659\/AJCR.922498","article-title":"Myocardial infarction with limb arterial and venous thrombosis in a patient with enoxaparin-induced thrombocytopenia","volume":"21","author":"Singh","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.amjmed.2021.10.023","article-title":"First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study","volume":"135","author":"Sogaard","year":"2022","journal-title":"Am. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.diabres.2008.01.019","article-title":"Heparin-induced hyperkalemia","volume":"80","author":"Thomas","year":"2008","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.2146\/news100063","article-title":"Fda approves first generic enoxaparin product","volume":"67","author":"Thompson","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B56","first-page":"166","article-title":"Hyperkalemia due to low-molecular-weight heparin","author":"van der Heiden","year":"2022","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"B57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10557-021-07251-6","article-title":"Low molecular weight heparin, anti-inflammatory\/immunoregulatory and antiviral effects, a short update","volume":"37","author":"Vitiello","year":"2023","journal-title":"Cardiovasc Drugs Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"119818","DOI":"10.1016\/j.carbpol.2022.119818","article-title":"Heparin: an old drug for new clinical applications","volume":"295","author":"Wang","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0208725","DOI":"10.1371\/journal.pone.0208725","article-title":"The efficacy and safety of pharmacologic thromboprophylaxis following caesarean section: a systematic review and meta-analysis","volume":"13","author":"Yang","year":"","journal-title":"PLoS One"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/aogs.13359","article-title":"Efficacy of low-molecular-weight heparin on the outcomes of in vitro fertilization\/intracytoplasmic sperm injection pregnancy in non-thrombophilic women: a meta-analysis","volume":"97","author":"Yang","year":"","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e19266","DOI":"10.2196\/19266","article-title":"Complementing the us Food and drug administration adverse event reporting system with adverse drug reaction reporting from social media: comparative analysis","volume":"6","author":"Zhou","year":"2020","journal-title":"JMIR Public Health Surveill."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s43032-021-00678-0","article-title":"Low molecular weight heparins (lmwh) and implications along pregnancy: a focus on the placenta","volume":"29","author":"Zullino","year":"2022","journal-title":"Reprod. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1442002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:26:58Z","timestamp":1723422418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1442002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":62,"alternative-id":["10.3389\/fphar.2024.1442002"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1442002","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"article-number":"1442002"}}